The voucher, which is transferable, allows a drug developer to expedite the review process of its product even if it does not fit requirements for a quick process. This would be the third priority voucher sale for bluebird after selling two for a combined $197 million over the past one year.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment